Quick Answer
Yes, Medicare Part B covers Hyalgan injections for knee osteoarthritis when medical necessity criteria are met. Hyalgan was one of the first FDA-approved hyaluronic acid products in the United States and has extensive clinical data supporting its use. Most patients pay 20% coinsurance after their Part B deductible.
Medicare Part B Coverage for Hyalgan
Hyalgan is a sodium hyaluronate injection made by Fidia Pharma. It received FDA approval in 1997, making it one of the earliest viscosupplementation products available in the U.S. Medicare has covered Hyalgan since its approval, and this coverage has remained stable for nearly three decades.
Key coverage facts:
- Covered under Part B as a physician-administered injectable
- No prior authorization required under Original Medicare
- Subject to Local Coverage Determinations (LCDs) from your regional MAC
- Must meet medical necessity criteria documented in your medical records
- Long clinical history: FDA-approved since 1997 with extensive safety data
Coverage Requirements
Medical Necessity Criteria
For Medicare to pay for Hyalgan, your medical records must show:
- Diagnosis of knee osteoarthritis with ICD-10 code M17.x
- Failure of conservative treatment for at least 3 months, including physical therapy, oral pain medications (NSAIDs), or activity modification
- Chart documentation showing conservative approaches did not provide enough relief
- X-ray evidence confirming osteoarthritis (most MACs require imaging within the past 12 months)
Billing Codes
| Code | Description | 2026 Estimated Allowable |
|---|---|---|
| J7321 | Hyalgan (sodium hyaluronate), per dose | $150 - $250 per injection |
| 20610 | Arthrocentesis, large joint (knee) | $85 - $110 |
| 77002 | Fluoroscopic guidance (if used) | $75 - $95 |
Note: Hyalgan shares J-code J7321 with Supartz FX. Your provider will specify the product on the claim form. The code is billed for each injection in the series.
Frequency Limits
- Medicare typically covers one treatment course (3-5 weekly injections) per knee every 6 months
- Some MACs allow repeat treatment after 6 months if the initial series gave meaningful relief
- Bilateral knee treatment is generally covered when both knees have documented OA
- Your provider should document the clinical benefit from prior treatment to support repeat courses
Your Out-of-Pocket Costs
| Item | Amount |
|---|---|
| Part B deductible (2026) | $257/year |
| Coinsurance | 20% of Medicare-approved amount |
| Typical total patient cost | $100 - $300 per treatment course |
| With Medigap | May cover the 20% coinsurance |
Example Cost Calculation
If Medicare approves $200 per injection for a 5-injection course ($1,000 total):
- Medicare pays: $800 (80%)
- You pay: $200 (20%)
- If you have a Medigap plan: your supplement may cover some or all of that $200
Medicare Advantage Plans
If you have a Medicare Advantage (Part C) plan:
- Coverage generally follows Original Medicare guidelines
- Prior authorization may be required — check with your plan first
- Copays vary by plan and may differ from the standard 20% coinsurance
- Network restrictions may apply — verify your provider is in-network
- Contact your plan’s member services to confirm coverage before your appointment
What If Medicare Denies Coverage?
If your Hyalgan claim is denied:
- Request the denial reason in writing
- Gather supporting documents including X-rays, treatment records, and your provider’s letter of medical necessity
- File a redetermination (Level 1 appeal) within 120 days
- Highlight Hyalgan’s long track record — its decades of FDA approval and clinical evidence support medical necessity
Many initial denials are overturned on appeal with proper documentation.
Hyalgan Product Details
| Feature | Detail |
|---|---|
| Manufacturer | Fidia Pharma |
| Active ingredient | Sodium hyaluronate |
| Injection schedule | 3 to 5 injections, given 1 week apart |
| FDA-approved for | Knee osteoarthritis |
| Molecular weight | 500,000 - 730,000 daltons (low molecular weight) |
| Source | Avian-derived (chicken comb extract) |
| Volume per injection | 2 mL |
Hyalgan was one of the first hyaluronic acid injectables FDA-approved for knee osteoarthritis in the United States. Its low molecular weight formulation has been studied in numerous clinical trials, and it has a well-established safety profile spanning nearly 30 years of clinical use.
Frequently Asked Questions
How often will Medicare pay for Hyalgan?
Medicare generally covers one treatment course per knee every 6 months. A treatment course consists of 3 to 5 weekly injections, depending on your provider’s clinical judgment. Documentation of clinical response helps support repeat treatment.
Do I need prior authorization for Hyalgan under Medicare?
No. Original Medicare does not require prior authorization for Hyalgan. If you have a Medicare Advantage plan, your plan may have its own prior authorization rules. Check with your plan before scheduling treatment.
Is Hyalgan covered under Medicare Advantage?
Yes. Medicare Advantage plans must cover all services that Original Medicare covers. Your plan may have different cost-sharing, provider network requirements, or prior authorization policies. Call your plan for details.
What is the difference between Hyalgan and Genvisc 850?
Genvisc 850 is sometimes referred to as a biosimilar to Hyalgan, sharing a similar molecular weight and composition. Both use the same J-code (J7321). Your provider can discuss which product is available and appropriate for your treatment. Medicare covers both.
Does Hyalgan contain animal products?
Yes. Hyalgan is derived from chicken combs. If you have allergies to poultry, feathers, or eggs, inform your doctor. Non-avian alternatives such as Euflexxa are available and also covered by Medicare.